CSPC Group (01093): SYH2085 tablets approved for clinical trials in China

According to the Zhitong Finance App, Shiyao Group (01093) issued an announcement. The SYH2085 tablets developed by the Group have been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China.

This product is an innovative chemical class 1 drug independently developed by the Group. It is a novel oral small molecule drug candidate that can inhibit the activity of RNA polymerase acid acid protein (PA) endonuclease in influenza viruses. The clinical indications approved this time are for the treatment of simple influenza A and B in adults and adolescents aged 12 and above. Preclinical studies have shown that the product shows clear, broad-spectrum, and excellent inhibitory effects on influenza A and B viruses, can effectively reduce viral load and influenza-like symptoms in animal influenza models, and has good pharmacokinetic properties and safety.

This product is expected to become an effective drug for treating influenza, has high clinical development value, and will further enrich the Group's product pipeline in the field of anti-infective treatment.